Details for New Drug Application (NDA): 215211
✉ Email this page to a colleague
The generic ingredient in OPFOLDA is miglustat. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the miglustat profile page.
Summary for 215211
| Tradename: | OPFOLDA |
| Applicant: | Amicus Therap Us |
| Ingredient: | miglustat |
| Patents: | 10 |
Pharmacology for NDA: 215211
| Mechanism of Action | Enzyme Stabilizers Glucosylceramide Synthase Inhibitors |
Suppliers and Packaging for NDA: 215211
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OPFOLDA | miglustat | CAPSULE;ORAL | 215211 | NDA | AMICUS THERAPEUTICS US, LLC | 71904-300 | 71904-300-01 | 4 BOTTLE, PLASTIC in 1 BOTTLE, PLASTIC (71904-300-01) / 1 CAPSULE in 1 BOTTLE, PLASTIC |
| OPFOLDA | miglustat | CAPSULE;ORAL | 215211 | NDA | AMICUS THERAPEUTICS US, LLC | 71904-300 | 71904-300-02 | 24 BOTTLE, PLASTIC in 1 BOTTLE, PLASTIC (71904-300-02) / 1 CAPSULE in 1 BOTTLE, PLASTIC |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 65MG | ||||
| Approval Date: | Sep 28, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 28, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 30, 2035 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | THE TREATMENT OF POMPE PATIENTS | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 7, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | THE TREATMENT OF POMPE PATIENTS | ||||||||
Complete Access Available with Subscription
